Could a combination of cancer drugs for adults also treat neuroblastoma in children? | Fierce Biotech
Stimulation of an anti-tumor immune response with “chromatin-damaging” therapy | SpringerLink
FACT Complex-targeting Curaxin CBL0137 for Refractory Lymphomas Clinical Trial | Power
CBL0137 | ≥99%(HPLC) | Selleck | NF-κB inhibitor
Frontiers | Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms | Oncology
New Strategy For Stubborn Neuroblastomas
Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pan
Acute exposure to CBL0137 decreases CD133 cell-surface expression and... | Download Scientific Diagram
CBL0137 preferentially kills GSCs over NSTCs by targeting FACT. A, GSCs... | Download Scientific Diagram
CBL0137 inhibits EPC in vitro. a A 13-nucleosome 601207 × 13 array for... | Download Scientific Diagram
Australian Researchers Find New Way to Target Deadly Childhood Cancer With CBL0137 | The Cure Starts Now
The small molecule drug CBL0137 increases the level of DNA damage and the efficacy of radiotherapy for glioblastoma - ScienceDirect
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137 | Cell Death & Disease
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137 | Cell Death & Disease
The anti-cancer drugs curaxins target spatial genome organization | Nature Communications
Potent antileukemic activity of curaxin CBL0137 against MLL‐rearranged leukemia - Somers - 2020 - International Journal of Cancer - Wiley Online Library
IJMS | Free Full-Text | Exploring the Interaction of Curaxin CBL0137 with G-Quadruplex DNA Oligomers | HTML
Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Pr
Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG
Potent antileukemic activity of curaxin CBL0137 against MLL‐rearranged leukemia - Somers - 2020 - International Journal of Cancer - Wiley Online Library
The small molecule drug CBL0137 increases the level of DNA damage and the efficacy of radiotherapy for glioblastoma - ScienceDirect
Frontiers | The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression | Oncology
Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pan
Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma
Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG
Potent antileukemic activity of curaxin CBL0137 against MLL‐rearranged leukemia - Somers - 2020 - International Journal of Cancer - Wiley Online Library
